CCTG Clinical Trials
Public Trial Select
Member Trial Select
TAILORx | MAC12 trial showed no benefit from chemotherapy for women with breast cancerClinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment. More >> |
Recently Activated Trials
Member Links
CCTG’s MA.39 trial receives green light from funding bodiesOne of the most promising advances in cancer treatment is the use of biological markers or biomarkers to identify the therapies a particular cancer may or may not respond to. More >> |
Planned Trials
Committees Select
Experimental Leukemia Combination Proves Toxic for Older, Frail Patients
Presented at the 61st American Society of Hematology (ASH) Annual Meeting
About 32 percent of older, sicker patients enrolled on a leukemia clinical trial experienced serious side effects from a treatment that combined a chemotherapy and an immunotherapy drug, leading investigators to pause the trial and the U.S. Food and Drug Administration to eventually pull the combination from the current study. The study was presented by Dr. Annette Hay at the 61st American Society of Hematology (ASH) Annual Meeting the world’s largest conference devoted to blood diseases and blood cancers like lymphoma, the findings serve as both triumph and warning.
More >>
Donation helps advance research
The establishment of the Britton Smith Foundation Clinical Trials Fund. A thank you from Doug Kane, senior manager, Canadian Cancer Society FLA & The Waterways Community Office.
More >>
Cell Therapy’s Promise for Canadians Must Include Access
An emerging form of immunotherapy, called adoptive cell transfer, has the potential to transform the way in which cancers are treated.
More >>
Palliative and supportive care presentation at ESMO 2019
Approximately a fifth of patients participating in phase III breast, lung, or colorectal cancer clinical trials conducted by CCTG also used complementary medicines.
More >>
Innovative study advances personalized medicine for prostate cancer patients
CCTG IND224 is a new clinical trial, opening across Canada, is considered a major advancement in precision medicine for prostate cancer and the first of its kind in the world.
More >>
CCTG LY16 | RELEVANCE published in New England Journal of Medicine
The results of the CCTG LY16 trial of Rituxmab plus Lenalidomide in Advanced Untreated Follicular Lymphoma (RELEVANCE), recently published in New England Journal of Medicine, has the potential to offer a new treatment option to lymphoma patients, that does not require chemotherapy.
More >>
The rise of precision medicine
Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.
More >>Planned trials
CEC7
Post-Surgical (SRS) Compared with (FSRS) for Resected Metastatic Brain Disease
GCC1
Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumours
Recently activated
The rise of precision medicine
Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.
More >>
TAILORx | MAC12 trial showed no benefit from chemotherapy for women with breast cancer
Clinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment.
More >>
Study results suggest that a new pancreatic cancer treatment regimen should become standard practice world-wide
Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.
More >>
Canadian Cancer Research Alliance announces award winners
Canadian Cancer Research Alliance has announced the recipients of their 2017 awards: former CCTG Director, Dr. Elizabeth Eisenhauer will recieve the Exceptional Leadership in Cancer Research award and Ms. Judy Needham will receive the Exceptional Leadership in Patient Involvement in Cancer award.
More >>Publications
Optimizing whole brain radiotherapy dose and fractionation: Results from a prospective phase III trial (NCCTG N107C (Alliance)/CEC.3)
International Journal of Radiation Oncology*Biology*Physics 106: 255 - 260, 2020
Trifiletti DM;Ballman KV;Brown PD;Anderson SK;Carrero XW;Cerhan JH;Whitton AC;Greenspoon J;Parney IF;Laack NN;Ashman JB;Bahary JP;Hadjipanayis CG;Urbanic JJ;Barker FG;Farace E;Khuntia D;Giannini C;Buckner JC;Galanis E;Roberge D;
Unusual Carfilzomib Toxicity: Three Cases of Drug-induced Thrombotic Microangiopathy (TMA) after Treatment with High-dose weekly Carfilzomib, Cyclophosphamide, and Dexamethasone (wCCD)
Clinical Lymphoma Myeloma and Leukemia 19: e272 - e273, 2019
Monteith B;Venner C;Reece D;Kew A;Lalancette M;Garland J;Shepherd L;McDonald G;Gul E;Pater J;Hay A;
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
N Engl J Med 381: 121 - 131, 2019
Davis ID;Martin AJ;Stockler MR;Begbie S;Chi KN;Chowdhury S;Coskinas X;Frydenberg M;Hague WE;Horvath LG;Joshua AM;Lawrence NJ;Marx G;McCaffrey J;McDermott R;McJannett M;North SA;Parnis F;Parulekar W;Pook DW;Reaume MN;Sandhu SK;Tan A;Tan TH;Thomson A;Tu E;Vera-Badillo F;Williams SG;Yip S;Zhang AY;Zielinski RR;Sweeney CJ;
Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer (ONLINE)
Clinical epigenetics 11: 155 - 155, 2019
Snider H;Villavarajan B;Peng Y;Shepherd LE;Robinson AC;Mueller CR;
Complementary medicine (CM) use in phase III clinical trials (P3T) conducted by the Canadian Cancer Trials Group (CCTG)
Ann Oncol 30, 2019
Wells JC;Sidhu A;Ding K;Heng DYC;Shepherd F;Ellis PM;Bradbury PA;Jonker DJ;Moore M;Siu LL;Gelmon KA;Karapetis C;Shapiro J;Nott L;O'Callaghan CJ;Parulekar WR;Seymour LK;Smoragiewicz M;Monzon JG;
LBA18Clinical outcomes by chemotherapy regimen in patients with RS 26-100 in TAILORx
Ann Oncol 30, 2019
Sparano J;Gray RJ;Makower D;Albain K;Saphner TJ;Badve S;Wagner L;Mihalcioiu C;Desbiens C;Hayes DF;Dees EC;Geyer C;Olson J;Wood WC;Lively T;Paik S;Ellis M;Abrams JS;Sledge GW;
Canadian cancer trials group trial IND.231: A phase 1 trial evaluating CX-5461, a novel first-in-class G-quadruplex stabilizer in patients with advanced solid tumors enriched for DNA-repair deficiencies
San Antonio Breast Cancer Symposium , 2019
Hilton J;Gelmon K;Cescon D;Tinker A;Jonker D;Goodwin R;Laurie S;Hansen A;Aparicio S;Soong J;Hagerman L;Lui H;Bedard P;Pritchard K;Tu D;Seymour L;
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205
Clinical Genitourinary Cancer 17: 201 - 208, 2019
Hotte SJ;Chi KN;Joshua AM;Tu D;Macfarlane RJ;Gregg RW;Ruether JD;Basappa NS;Finch D;Salim M;Winquist EW;Torri V;North S;Kollmannsberger C;Ellard SL;Eigl BJ;Tinker A;Allan AL;Beja K;Annala M;Powers J;Wyatt AW;Seymour L;